Immune-Mediated Inflammatory Diseases
Conditions
Interventions
Sponsors
Mianyang Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Participants with a diagnosis of rheumatoid arthritis, ankylosing spondylitis or plaque psoriasis 2.Decision to initiate ADA treatment in accordance with routine medical practice and in compliance with eligibility for adalimumab based on the local label 3.Prior to any study-specific procedures, participant has voluntarily signed the authorization (or informed consent where applicable) to disclose and use anonymized personal health information after participate in this research.
Exclusion criteria
Exclusion criteria: 1.Inadequate response to previous standard treatment with anti-tumor necrosis factor (TNF) biological agent according to the physician's clinical judgment. 2.Participant has been treated with adalimumab within 70 days (five half-lives) prior to the Baseline Visit. 3.Participants discontinued due to adverse drug reaction of previous adalimumab treatment. 4.Participants who fulfill any of the contraindications as per adalimumab label in China. 5.Participants, who in the clinician's view, may not be able to comply with the study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EuroQoL-5 Dimension; | — |
Secondary
| Measure | Time frame |
|---|---|
| WPAI-SHP;PtGA;DLQI;BASDAI;PGA;PASI;SJC28;TJC28; | — |
Countries
China
Contacts
Public ContactYing Gu
Mianyang Hospital of Traditional Chinese Medicine
Outcome results
None listed